Page 22 - GALENIKA MEDICAL JOURNAL

Literatura 17. Lax SJ, Harvey J, Axon E, Howells L, Santer M, Ridd MJ, et al. Strategies
for using topical corticosteroids in children and adults with eczema.
Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013356.
1. Kendall EC. The development of cortisone as therapeutic agent. Nobel
Lecture, 11 december 1950. Available at: https://www.nobelprize.org/ 18. Tier HL, Balogh RA, Bashyam AM, Fleischer AB, Spergel
uploads/2018/06/kendall-lecture.pdf. [Assessed: 10.february 2022] JM, Masicampo EJ, et al. Tolerability of and Adherence to
Topical Treatments in Atopic Dermatitis: A Narrative Review.
2. Sulzberger MB, Witten VH. The effect of topically applied compound Dermatol Ther (Heidelb). 2021 Apr;11(2):415-31.
F in selected dermatoses. J Invest Dermatol. 1952 Aug;19(2):101-2.
19. Felix K, Unrue E, Inyang M, Cardwell LA, Oussedik E, Richardson
3. Katz M, Gans EH. Topical corticosteroids, structure-activity and I, et al Patients preferences for different corticosteroid vehicles
the glucocorticoid receptor: discovery and development-a process are highly variable. J Dermatolog Treat. 2020 Mar;31(2):147-51.
of “planned serendipity”. J Pharm Sci. 2008 Aug;97(8):2936-47.
20. Kuehl B, Shear NH. The Evolution of Topical Formulations
4. Timmermans S, Souffriau J, Libert C. A General Introduction to in Psoriasis. Skin Therapy Lett. 2018 Jul;23(4):5-9.
Glucocorticoid Biology. Front Immunol. 2019 Jul 4;10:1545.
21. Teixeira A, Teixeira M, Almeida V, Gaio R, Torres T, Magina S, et al.
5. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira Does the Vehicle Matter? Real-World Evidence on Adherence to Topical
J, et al. Mechanisms of action of topical corticosteroids Treatment in Psoriasis. Pharmaceutics. 2021 Sep 23;13(10):1539.
in psoriasis. Int J Endocrinol. 2012;2012:561018.
22. Hong CH, Papp KA, Lophaven KW, Skallerup P, Philipp S. Patients
6. Wiedersberg S, Leopold CS, Guy RH. Bioavailability with psoriasis have different preferences for topical therapy,
and bioequivalence of topical glucocorticoids. Eur highlighting the importance of individualized treatment
J Pharm Biopharm. 2008 Mar;68(3):453-66. approaches: randomized phase IIIb PSO-INSIGHTFUL study.
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1876-83.
7. Piacquadio D, Kligman A. The critical role of the vehicle
to therapeutic efficacy and patient compliance. J Am 23. Okwundu N, Cardvell LA, Cline AE, Richardson IM, Feldman SR.
Acad Dermatol. 1998 Aug;39(2 Pt 3):S67-73. Adherence to Topical Treatment Can Improve Treatment-Resistant
Moderate Psoriasis. Cutis. 2020 Feb;105(2):89-91;E2;E3.
8. Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M,
Agarwal S. Topical corticosteroids in dermatology. Indian J 24. Kulawik-Pióro A, Miastkowska M. Polymeric Gels and
Dermatol Venereol Leprol. 2016 Jul-Aug;82(4):371-8. Their Application in the Treatment of Psoriasis Vulgaris:
A Review. Int J Mol Sci. 2021 May 12;22(10):5124.
9. Teixeira A, Vasconcelos V, Teixeira M, Almeida V, Azevedo
R, Torres T, et al. Mechanical Properties of Topical Anti- 25. Guenther L. Current management of scalp psoriasis.
Psoriatic Medicines: Implications for Patient Satisfaction with Skin Therapy Lett. 2015 May-Jun;20(3):5-7.
Treatment. AAPS PharmSciTech. 2019 Jan 2;20(1):36.
26. Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al.
10. Del Rosso JQ. Use of Individual Components and The Alopecia Areata Consensus of Experts (ACE) study: Results
Advances in Topical Formulation Technology: Focus on of an international expert opinion on treatments for alopecia
Corticosteroids. Cosmetic Dermatol. 2006;19(11):677-80. areata. J Am Acad Dermatol. 2020 Jul;83(1):123-130.
11. Habet KA, Kolli SS, Pona A, Feldman SR. A review of topical 27. Strazzulla MA, Wang EHC, Avila L, Sicco KL, Brinster N,
corticosteroid sprays for the treatment of inflammatory dermatoses. Christiano AM, et al. Alopecia areata: An appraisal of
Dermatol Online J. 2019 Aug 15;25(8):13030/qt0855j2zz. new treatment approaches and overview of current
therapies. J Am Acad Dermatol. 2018 Jan;78(1):15-24.
12. Humbert P, Guichard A. The topical corticosteroid
classification called into question: towards a new 28. Buajeeb W, Pobrurksa C, Kraivaphan P. Efficacy of fluocinolone
approach. Exp Dermatol. 2015 May;24(5):393-5. acetonide gel in the treatment of oral lichen planus. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod. 2000 Jan;89(1):42-5.
13. Zvidzayi M, Rath S, Bon C, Abboo S, Kanfer I. A Novel
Approach to Assess the Potency of Topical Corticosteroids.
Pharmaceutics. 2021 Sep 13;13(9):1456.
14. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical
glucocorticosteroids. J Am Acad Dermatol. 2006 Jan;54(1):1-15.
15. Spada F, Barnes TM, Greive KA. Comparative safety and efficacy Konflikt interesa: Nema
of topical mometasone furoate with other topical corticosteroids.
Australas J Dermatol. 2018 Aug;59(3):e168-e174. Primljeno: 27. 02. 2022.
Prihvaćeno: 21. 04. 2022.
16. Long CC, Finlay AY. The finger-tip unit--a new practical
measure. Clin Exp Dermatol. 1991 Nov;16(6):444-7. Onlajn: 30. 06. 2022.

22 DOI: 10.5937/Galmed2202017G